----- GAPE — Complete Biological Physics Validation Package (Informational Actualization Model applied to mammalian somatic cell architecture)

Complete biological physics validation package for the Informational Actualization Model (IAM) applied to mammalian somatic cell architecture, snapshot as of April 17, 2026. Core claim. Every mammalian somatic cell class has a minimum thermodynamic cost for maintaining its epigenomic identity through cell division, derived from the Landauer principle applied to DNMT1-mediated CpG methylation maintenance at physiological temperature. This defines a class-specific Shannon entropy floor, H_min. The ratio of observed entropy to floor is a single dimensionless index — the A-score. In health, A ≈ 1.0. Cancer is a measurable departure from it. The detection threshold A > 1.05 was derived entirely from healthy-cell requirements; no cancer data was used to set it. Five substrates, one framework. The same formula applies identically across five independent physical substrates — DNA methylation, nucleosome occupancy, nucleosome fuzziness, windowed protection score, and cfDNA fragment size entropy. All five H_min values are now MCMC-confirmed with R-hat < 1.001. Primary validation results: G-002 MCMC (methylation): H_min posteriors for 8 architecture classes validated against 37 published reference cell measurements. 17 chains, R-hat < 1.001, 800,000 samples. Principal discovery: immune class correction from 0.795 to 0.8389 ± 0.004 (6.44σ tension resolved by neutrophil reference data). G-003b MCMC (four additional substrates): 32 posteriors (8 classes × 4 substrates), 5 chains × 32 walkers × 5,500 steps, R-hat < 1.001, 800,000 samples per substrate, 42.1-second runtime on standard laptop. G-008 zero-free-parameter cancer prediction: A_tumor > A_normal correctly predicted for 27 of 28 TCGA cancer types across 4,304 matched tumor-normal pairs. TGCT architectural inversion predicted and confirmed. DCIS stratification: physics-derived threshold sits between low-grade DCIS (A = 1.045) and high-grade DCIS (A = 1.101). Alzheimer's disease: terminal-class A-score elevation confirmed in ROSMAP (n = 740) and BDR (n = 631) cohorts. Signal 20–40× smaller than GBM — same floor, different failure mode. E(a_bio) activation function: recovers biological actualization ceiling t_max = 120.3 ± 7.1 years, consistent with Gompertz-Makeham human lifespan limit. n_bio ordering: Spearman ρ = 0.905 (p = 0.002) between engine estimates and published Seahorse OCR/ECAR data across 8 architecture classes. Extended validation record (35 studies total). VAL-001 through VAL-013 cover methylation-substrate validation (TCGA field effect p = 1.32×10⁻¹⁵, OSK rejuvenation 85% reversal, cross-species canine confirmation at 70 million years divergence, pre-cancer window A = 1.01–1.05, HCC combined score with 8× separation from cirrhosis). VAL-014 through VAL-033 extend to the four non-methylation substrates (MESA theory with d_combined/d_single = 1.15× interpretation, nucleosome occupancy in breast cancer, fuzziness in prostate grading, WPS in 15 tissues 8 years before MESA, fragment size AUC = 0.940 across 7 cancers, field effect confirmed in all four substrates at p < 10⁻¹¹). VAL-034 through VAL-036 cover pan-mammalian and vertebrate extension predictions. Eight things the data established. Field cancerization is substrate-independent (thermodynamic phenomenon, not a methylation artifact). H_min is species-independent (0.004 A-score difference across 70 million years). Brain tumors produce the largest signal of any cancer type tested (LGG ΔA = 0.273, GBM ΔA = 0.228). The pre-cancer window A = 1.01–1.05 is substrate-independent (geometric property of the Shannon curve). MESA explained from first principles (inter-substrate r = 0.54, ceiling AUC = 1.000). Normal aging does not reach the cancer threshold (~1,075-year extrapolation). D+Q senolytic therapy — only GAPE moves in the correct direction; all published clocks move wrongly. Five zero-free-parameter clinical test designs emerge from the framework (HCC combined score, CSF glioma grading, TGCT inversion as universal negative control, multi-fluid triage protocol, D+Q reversibility pharmacodynamic readout). Honest caveats disclosed. VAL-003 pipeline normalization (sesame vs GenomicStudio offset), VAL-003 pair count reconciliation (4,304 live vs 4,092 analyzable), VAL-002 cell fraction QC outside Salas 2018 range, VAL-004 global-mean beta proxy, VAL-007 healthy class means below 1.0 (pipeline offset), VAL-012 D+Q global-mean proxy awaiting class-stratified EPIC, non-methylation slope amplification from Shannon curve geometry. Disclosed before referees raise them. Contents. Preprint PDF and LaTeX source. HTML evidence report with expandable detail tables (VAL-003 per-cancer, VAL-007 per-cancer cfDNA, VAL-008+009 specimen matrix, VAL-012 clock comparison, full G-003b posteriors). Evidence database in JSON and TSV formats with full provenance. MCMC chain generator scripts (deterministic — chains reproducible from seeds in 42 seconds). Validation scripts VAL-001 through VAL-036. Figure generation script. Reproducibility. Every result reproducible from included scripts. All beta values from publicly available primary sources cited in the scripts and paper bibliography. Provenance hashes for each data entry included. Python 3.9+ with pip install numpy scipy. No proprietary data. No API keys. Relationship to IAM cosmology. This work is the biological application of the Informational Actualization Model, an independent cosmological research program applying the Landauer principle universally across physical scales. The IAM cosmological validation package is archived separately (DOI 10.5281/zenodo.18702042). The biological work stands on its own empirical validation and does not require the cosmological work to be evaluated. Patent status. Analytical methodology protected under U.S. Provisional Patent Applications 64/012,720 (filed March 21, 2026) and 64/014,568 (filed March 23, 2026). Derived results and biological tools released as open science with no commercial restriction on research use. Preprint, April 2026. All predictions tested against published data only. Prospective clinical validation has not been performed. Live interactive demonstration and continuously-updated evidence report: iamperformance.net GitHub repository: github.com/hmahaffeyges/IAM-Validation